News & Updates

Show Multimedia Only

Product Highlight - Linezolid (Lizod)

25 Nov 2025

Film-coated tablet 600 mg and Solution for injection for IV infusion 2 mg/mL x 300 mL

Product Highlight - Linezolid (Lizod)

25 Nov 2025

Product Highlight - Losartan potassium, amlodipine besilate (RiteMED Losartan potassium + Amlodipine besilate)

25 Nov 2025

Film-coated tablet 50 mg/5 mg, 100 mg/5 mg and 100 mg/10 mg

Product Highlight - Losartan potassium, amlodipine besilate (RiteMED Losartan potassium + Amlodipine besilate)

25 Nov 2025

Product Highlight - Levodropropizine (Extusiv)

25 Nov 2025

Syrup 30 mg/5 mL

Product Highlight - Levodropropizine (Extusiv)

25 Nov 2025

Product Highlight - Tiotropium bromide (Aviar)

25 Nov 2025

Dry powder for inhalation (pre-metered dose) 18 mcg

Product Highlight - Tiotropium bromide (Aviar)

25 Nov 2025

Product Highlight - Dienogest (Riliz)

25 Nov 2025

Film-coated tablet 2 mg

Product Highlight - Dienogest (Riliz)

25 Nov 2025

Product Highlight - Somatostatin acetate (Somaset)

25 Nov 2025

Powder for injection 3 mg

Product Highlight - Somatostatin acetate (Somaset)

25 Nov 2025

Product Highlight - Acetylcysteine (Fluimucil)

25 Nov 2025

Effervescent tablet 600 mg and Granules for oral solution 600 mg

Product Highlight - Acetylcysteine (Fluimucil)

25 Nov 2025

Genetic structures predict adverse response to chemotherapy in breast cancer patients

24 Nov 2025

Certain genetic structures among patients with breast cancer are associated with adverse response to chemotherapy, reports a recent study.

Genetic structures predict adverse response to chemotherapy in breast cancer patients

24 Nov 2025

Dalbavancin safe, effective in paediatric Gram-positive infections

23 Nov 2025

Consolidation treatment with dalbavancin appears safe and effective for the treatment of severe infections caused by Gram-positive microorganisms in children, suggests a study.

Dalbavancin safe, effective in paediatric Gram-positive infections

23 Nov 2025

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

22 Nov 2025

Treatment with immune checkpoint inhibitors (ICI) is safe and feasible in patients with aggressive pituitary neuroendocrine tumours (PNTs), a recent study has shown.

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

22 Nov 2025

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Product Highlight - Linezolid (Lizod)

Product Highlight - Linezolid (Lizod)

Product Highlight - Losartan potassium, amlodipine besilate (RiteMED Losartan potassium + Amlodipine besilate)

Product Highlight - Losartan potassium, amlodipine besilate (RiteMED Losartan potassium + Amlodipine besilate)

Product Highlight - Levodropropizine (Extusiv)

Product Highlight - Levodropropizine (Extusiv)

Product Highlight - Tiotropium bromide (Aviar)

Product Highlight - Tiotropium bromide (Aviar)

Product Highlight - Dienogest (Riliz)

Product Highlight - Dienogest (Riliz)

Product Highlight - Somatostatin acetate (Somaset)

Product Highlight - Somatostatin acetate (Somaset)

Product Highlight - Acetylcysteine (Fluimucil)

Product Highlight - Acetylcysteine (Fluimucil)

Genetic structures predict adverse response to chemotherapy in breast cancer patients

Genetic structures predict adverse response to chemotherapy in breast cancer patients

Dalbavancin safe, effective in paediatric Gram-positive infections

Dalbavancin safe, effective in paediatric Gram-positive infections

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours

ICI therapy safe to use in aggressive pituitary neuroendocrine tumours